Primer pair, gene probe, kit and application of primer pair, gene probe and kit in identification of mucor
Through RPA isothermal amplification technology and colloidal gold test strip detection, combined with specific primer pairs and gene probes, the complexity and cost problems of mucor bacteria detection are solved, and fast, sensitive and specific detection results are achieved. It is suitable for Grassroots and on-site applications.
Patent Information
- Application Number
- CN202411294352.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-11-19
AI Technical Summary
The existing mucor fungus detection methods have problems such as complex operation, long time, high cost, high risk of environmental pollution and are not suitable for grassroots or on-site inspections. They lack fast, sensitive, high specificity, simple operation and low cost detection methods.
RPA isothermal amplification technology combined with colloidal gold test strip detection, specific primer pairs and gene probes were designed, and visual inspection was carried out on the test strip after RPA amplification, and microsphere solution and colloidal gold technology were used to achieve rapid and accurate Mucor fungus identification.
It realizes fast, sensitive, high specificity, easy to operate and low-cost detection of mucor bacteria, avoids false positives caused by primer dimers, and provides a solution suitable for grassroots and on-site detection.
Smart Images

Figure CN118979121A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of rapid in vitro detection, and specifically relates to a primer pair, a gene probe and a kit and applications thereof in identifying Mucor. Background Art
[0002] Mucormycosis is a type of conditionally pathogenic fungal disease caused by infection with Mucor fungi, among which infections with the genera Trichoderma, Rhizopus, Absidia and Cunninghamella are the most common.
[0003] There are three ways for humans to contract mucormycosis: by inhaling spores, by swallowing spores in food or medicine, or by contaminating wounds with spores. Inhalation is the most common. We actually inhale spores of many fungi every day. However, our immune systems are healthy and our respiratory barriers are intact, so Mucor spores are cleared from the respiratory tract by cilia (tiny hairs attached to the lining of the respiratory tract that remove unwanted particles), preventing them from causing infection.
[0004] When our lungs are damaged and our immune systems are suppressed, once the endothelial cells (cells lining our blood vessels) are invaded, these spores can grow in the respiratory tract or sinuses, causing tissue death and necrosis, and invading body tissues. The first vulnerability for Mucor spores to be inhaled comes from the failure of our immune system. Mucor infections are quite rare. Mucor infections can occur in the lungs, but the nose-brain-orbital area is the most common site of infection. Nasal-orbital infections can further invade the eyes, causing blindness, or spread to the brain, causing symptoms of intracranial infection such as headaches and seizures. Mucor can also infect the skin. Life-threatening wound infections can occur after trauma caused by natural disasters or other reasons, or when the wound is contaminated by soil and water.
[0005] In vitro drug sensitivity studies have shown that species within the Mucor subphylum are relatively consistent in being resistant to voriconazole, fluconazole, and all echinocandins including caspofungin, micafungin, and anidulafungin. At present, amphotericin B is undoubtedly the most active drug against Mucor. So far, only C. griseus and C. echinμlata of the genus Cunninghamella, and A. ossiformis and A. variabilis of the genus Lepidoptera have been found to be resistant to amphotericin B.
[0006] At present, the methods for identification of Mucor are: imaging, histopathology, direct culture, serological methods, drug sensitivity testing, molecular methods, etc., or detection by PCR method, and although the PCR method is short in time, it is relatively cumbersome, has too high requirements for the laboratory, and is not suitable for clinical promotion. These conventional detection methods have long operation time, too high requirements for the laboratory, rely on expensive experimental equipment, and are complicated for strain separation and processing operations and have certain infection risks, which are not convenient for detection at the grassroots level or on-site. Therefore, it is necessary to develop a highly efficient, accurate, sensitive, easy-to-operate, and readily monitorable Mucor detection and analysis method, which is of great significance for the scientific research and application of Mucor.
[0007] RPA isothermal amplification technology, also known as recombinase polymerase amplification technology (RPA), is a new nucleic acid isothermal amplification technology developed by Piepenburg et al. in 2006 using protein recombination and repair involved in cell DNA synthesis. It is known as a nucleic acid detection technology that can replace PCR. RPA technology mainly relies on three enzymes: recombinase that can bind to single-stranded nucleic acids (oligonucleotide primers), single-stranded DNA binding protein (SSB) and strand displacement DNA polymerase. The reaction process of RPA is first that the recombinase binds to the primer to form a protein-DNA complex, and then the protein-DNA complex searches for homologous sequences in double-stranded DNA. Once the primer finds the target homologous sequence, a chain exchange reaction will occur to form and initiate DNA synthesis, and the exponential amplification of the target sequence on the template will be completed within a few minutes. The replaced DNA chain binds to SSB (single-stranded DNA binding protein) to keep the DNA in a single-stranded state and prevent it from being hydrolyzed by nucleases. The mixture of these three enzymes is also active at room temperature, with the optimal reaction temperature at around 39°C. With only a small amount of sample preparation, it can amplify as few as 1-10 DNA copies within 10 minutes. It has the advantages of high sensitivity, selectivity, portability, rapidity, and the ability to perform multiple amplifications.
[0008] The main principle of colloidal gold test strips is to use cellulose acetate membrane as a carrier, utilize the capillary action of the microporous membrane, and slowly transfer the liquid dripped on one end of the membrane strip to the other end, and use the colloidal gold to show the color reaction through the antigen-antibody binding of the streaked line. The biggest feature of this method is that it is simple to operate, fast and rapid, sensitive and accurate, safe and simple, low cost, and does not require professional personnel and instruments and equipment. The negative and positive color development is obvious, and the test results can usually be observed by the naked eye within 3-5 minutes.
[0009] Currently, the traditional methods for Mucor identification include: imaging, histopathology, direct culture, serological methods, drug sensitivity testing, molecular methods, NGS sequencing methods, etc.
[0010] The limitations of these traditional Mucor identification methods are:
[0011] 1. These identification methods all require the cultivation of Mucor strains, which takes a long time and is prone to contamination during the cultivation process.
[0012] 2. These identification methods can only identify a specific type of strain, and have serious lags in the diagnosis and treatment of diseases (after symptoms appear, the results cannot be known in time).
[0013] 3. Traditional bacterial molecular identification takes a long time (about 1-2 hours) to extract bacterial genomes, and the steps are complicated. Improper operation during the extraction process can easily cause environmental pollution.
[0014] 4. Conventional strain identification is costly and time-consuming, and is inconvenient and costly for clinical patients.
[0015] Therefore, there is an urgent need for a method for identifying Mucor that is rapid, sensitive, highly specific, easy to operate and low-cost. Summary of the invention
[0016] In order to solve the technical problem that the prior art lacks a method for identifying Mucor that is rapid, sensitive, highly specific, easy to operate and low-cost, the present invention provides a primer pair, a gene probe and a kit and their application in identifying Mucor based on RPA isothermal amplification and test strip detection technology.
[0017] The present invention designs a pair of conservative primers and probes in the conservative region of Mucor, and uses the RPA amplification method to establish a visual nucleic acid test strip detection technology for Mucor detection. The test first extracts the genome of the sample, then performs RPA amplification on the extracted sample, and finally drops the RPA-amplified sample onto the test strip, and the development of the test strip indicates whether the strain exists in the sample.
[0018] Rhizopus arrhizus and Mucor circinellodies both belong to the genus Mucor.
[0019] The first aspect of the present invention provides a primer pair for specific amplification of Mucor, the primer pair comprising a forward primer and a reverse primer, characterized in that the nucleotide sequence of the forward primer is as shown in SEQ ID NO: 1 or 2, and the nucleotide sequence of the reverse primer is as shown in SEQ ID NO: 3 or 4;
[0020] Preferably, the 5' end of the reverse primer is conjugated with a label, and the label is preferably biotin.
[0021] The second aspect of the present invention provides a gene probe coupled with digoxigenin labeling, the nucleotide sequence of the gene probe is shown in SEQ ID NO:6.
[0022] The third aspect of the present invention provides a primer-probe combination, wherein the primer-probe combination comprises the primer pair as described in the first aspect of the present invention and / or the gene probe as described in the second aspect of the present invention;
[0023] Preferably, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:1 and whose nucleotide sequence of the reverse primer is shown in SEQ ID NO:3, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:6; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:1 and whose nucleotide sequence of the reverse primer is shown in SEQ ID NO:4, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:6; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:2 and whose nucleotide sequence of the reverse primer is shown in SEQ ID NO:3, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:6; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:2 and whose nucleotide sequence of the reverse primer is shown in SEQ ID NO:4, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:6;
[0024] More preferably, the 5' end of the reverse primer is conjugated with a label, and the label is preferably biotin.
[0025] A fourth aspect of the present invention provides a test strip, the test strip comprising a sample pad, a conjugation pad, a nitrocellulose membrane and an absorption pad, the conjugation pad comprising microsphere solution 1 and microsphere solution 2; the nitrocellulose membrane comprising a detection line T line and a quality control line C line;
[0026] The microsphere solution 1 contains microspheres labeled with streptavidin; the microsphere solution 2 contains microspheres labeled with mouse anti-human antibody; the detection line T contains digoxigenin antibody, and the quality control line C contains goat anti-mouse antibody;
[0027] In some preferred embodiments, the test strip meets one or more of the following conditions:
[0028] (1) The particle size of the microspheres is 100-300 nm, for example, 200 nm;
[0029] (2) the molar concentration ratio of streptavidin in the microsphere solution 1 to the digoxigenin antibody in the detection line T is 1:1; and,
[0030] (3) The binding pad is a colloidal gold binding pad, and the amount of gold sprayed onto the microspheres is, for example, 6 μl / cm.
[0031] In the present invention, the detection line T has digoxin antibody, and the quality control line C has goat anti-mouse antibody; there are two kinds of microspheres on the colloidal gold binding pad: one is a microsphere labeled with streptavidin (SA), and the other is a microsphere labeled with mouse anti-human antibody. When the test strip is used for sample detection, since the amplified positive sample is labeled with biotin and digoxin, the sample is added to the glass fiber sample pad and flows to the colloidal gold binding pad. At this time, biotin will bind to the microspheres labeled with SA to generate a "microsphere-SA-biotin-positive fragment-digoxin" complex, which will reach the detection line T line along the flow direction. At this time, the complex will bind to the digoxin antibody and intercept the complex at the detection line T line, so the positive fragment will be colored on the detection line T line; if there is no positive fragment in the sample, the complex will not be formed, so the band will not appear on the detection line T line; another microsphere on the colloidal gold binding pad is a mouse anti-human microsphere, which will flow forward with the addition of the sample and will not react with the digoxin antibody on the detection line T line, but will continue to flow forward to the quality control line C line, react with the goat anti-mouse antibody on the quality control line C line, and the microsphere will be intercepted and colored at the quality control line C line.
[0032] The fifth aspect of the present invention provides a use of the primer pair as described in the first aspect of the present invention, the gene probe as described in the second aspect of the present invention, the primer-probe combination as described in the third aspect of the present invention and / or the test strip as described in the fourth aspect of the present invention in the preparation of a kit for identifying Mucor.
[0033] The sixth aspect of the present invention provides a kit for identifying Mucor, wherein the kit is selected from one or more of the primer pair described in the first aspect of the present invention, the gene probe described in the second aspect of the present invention, the primer-probe combination described in the third aspect of the present invention, and the test strip described in the fourth aspect of the present invention;
[0034] In some preferred embodiments, the kit further comprises a nucleic acid extraction reagent and / or a sample release buffer; the nucleic acid extraction reagent is an alkaline reagent, and the sample release buffer comprises a phosphate buffered saline solution;
[0035] In some more preferred embodiments, the nucleic acid extraction reagent is KOH and / or the sample release buffer is PBST+0.05% Triton.
[0036] In some embodiments, the method for preparing the test strip comprises the following steps:
[0037] i) preparing microsphere solution 1 and microsphere solution 2;
[0038] ii) The test strip is sprayed with gold film.
[0039] In some embodiments, the preparation of the microsphere solution 1 and the microsphere solution 2 in i) specifically comprises the following steps:
[0040] a) Mix the microspheres with a particle size of 100-300 nm and the activation buffer in two tubes at a volume ratio of 1:7;
[0041] b) Add streptavidin to the first tube at a final concentration of 0.1-0.15 mg / mL; add mouse anti-human antibody to the second tube at a final concentration of 0.1-0.15 mg / mL;
[0042] c) adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide at a final concentration of 1-10 mg / mL to the two tubes of solution in b) respectively, placing the mixture on a constant temperature shaker at a speed of 80-120 rpm and a temperature of 22-26° C. for reaction for 50-70 minutes;
[0043] d) After the reaction is completed, ultrasonicate, add blocking agents respectively, ultrasonicate, and continue to place in a constant temperature shaker at a speed of 80 to 120 rpm and a temperature of 22 to 26° C. for blocking, and the blocking time is 80 to 100 minutes;
[0044] e) After blocking, centrifuge for 20 minutes, discard the supernatant, resuspend the precipitates in the first tube and the second tube with PBS to obtain microsphere solution 1 and microsphere solution 2, and store them in a refrigerator at 2-8°C for later use.
[0045] In some preferred embodiments, the particle size of the microspheres is 200 nm; the activation buffer is a HEPES solution; the final concentration of streptavidin is 0.125 mg / mL; the final concentration of the mouse anti-human antibody is 0.125 mg / mL; the final concentration of 1-ethyl-(3-dimethylaminopropyl)carbodiimide is 1 mg / mL; the blocking agent is a CE510 solution; the rotation speed is 100 rpm, the temperature is 24°C, the reaction time is 60 mins; and the blocking time is 90 mins.
[0046] In some more preferred embodiments, the HEPES solution has a concentration of 5.6 g / L and a pH of 7.45.
[0047] In some embodiments, the test strip gold-sprayed film in ii) specifically comprises the following steps:
[0048] (1) diluting the microsphere solution 1 and the microsphere solution 2 prepared in step (i) by 15 to 25 times with a PBS solution;
[0049] (2) first spraying the diluted microsphere solution 1 of (1) onto the test strip at a concentration of 5 to 7 μl / cm, and drying; then spraying the diluted microsphere solution 2 of (1) onto the test strip at a concentration of 5 to 7 μl / cm, and drying;
[0050] (3) Using a film-spraying gold sprayer, digoxin antigen protein is sprayed on the nitrocellulose membrane as the detection line T line, and goat anti-mouse antibody is sprayed as the quality control line C line to obtain a test strip.
[0051] In some preferred embodiments, the dilution is 20-fold; and the concentration is 6 μl / cm.
[0052] The seventh aspect of the present invention provides a method for identifying Mucor in a sample to be tested for non-diagnostic purposes, the method comprising using the primer pair as described in the first aspect of the present invention, the gene probe as described in the second aspect of the present invention, the primer-probe combination as described in the third aspect of the present invention, the test strip as described in the fourth aspect of the present invention and / or the kit as described in the sixth aspect of the present invention;
[0053] In some preferred embodiments, the method comprises the following steps:
[0054] (I) performing RPA amplification on the DNA extracted from the sample to be tested using the primer pair described in the first aspect of the present invention, the gene probe described in the second aspect of the present invention, and / or the primer-probe combination described in the third aspect of the present invention to obtain an RPA amplification product; and,
[0055] (II) mixing the RPA amplification product and the sample release buffer in a volume ratio of 1:5, and adding the mixture to the test strip according to the fourth aspect of the present invention;
[0056] More preferably, the method further comprises:
[0057] (III) determining whether Mucor is present in the sample to be tested based on the information on the test strip obtained after implementing step (II);
[0058] The judgment conditions are: when the test strip has a detection line T line and a quality control line C line, it means that the result is positive and Mucor exists in the sample to be tested; when the test strip has only a quality control line C line but no detection line T line, it means that the result is negative and Mucor does not exist in the sample to be tested; when the test strip has no quality control line C line, the result is invalid.
[0059] In some embodiments, the DNA sample is obtained by a nucleic acid extraction reagent (alkaline reagent, such as KOH or NaOH).
[0060] In some embodiments, the nucleic acid extraction reagent is 0.1 M KOH.
[0061] In the present invention, the application scenarios of "non-diagnostic purpose" include, for example, detecting Mucor in the environment, detecting Mucor on the surface of contact lenses, etc.
[0062] An eighth aspect of the present invention provides a system for identifying Mucor, the system comprising:
[0063] (1) an information collection module: used to collect information on the test strip obtained after using the method according to the seventh aspect of the present invention; and,
[0064] (2) Identification module: used to determine whether the sample to be tested contains Mucor; the judgment criteria are:
[0065] a. If there is no quality control line C, the identification result is considered invalid; if there is a quality control line C, proceed to step b;
[0066] b. If there is a T line, it is judged as Mucor positive; if there is no T line, it is judged as Mucor negative;
[0067] (3) Data storage module: used to store user information, detection time, judgment results and other information, which includes user information, detection time and / or judgment results to facilitate the subsequent recording and tracking of pathogen infection information.
[0068] A ninth aspect of the present invention provides a computer-readable storage medium having a computer program stored thereon, wherein the computer program implements the identification system as described in the eighth aspect of the present invention.
[0069] The tenth aspect of the present invention provides an electronic device comprising a memory, a processor and a computer program stored in the memory and executable on the processor, wherein the processor implements the identification system as described in the eighth aspect of the present invention when executing the computer program.
[0070] The eleventh aspect of the present invention provides a primer pair as described in the first aspect of the present invention, the gene probe as described in the second aspect of the present invention, the primer-probe combination as described in the third aspect of the present invention, the test strip as described in the fourth aspect of the present invention, the kit as described in the sixth aspect of the present invention, the identification system as described in the eighth aspect of the present invention, the computer-readable storage medium as described in the ninth aspect of the present invention and / or the electronic device as described in the tenth aspect of the present invention for use in identifying whether a sample contains Mucor.
[0071] In some embodiments, the application is for non-diagnostic purposes, such as detecting Mucor in the environment, detecting Mucor on the surface of contact lenses, etc.
[0072] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0073] The reagents and raw materials used in the present invention are commercially available.
[0074] The positive and progressive effects of the present invention are:
[0075] The present application designs specific RPA amplification primers and gene probes for the conserved sequence gene fragments of Mucor, and can perform RPA amplification identification on all types of Mucor. The use of the specific amplification primers and gene probes of the present invention can effectively avoid the false positive phenomenon caused by the generation of primer dimers during the RPA amplification process, making the identification results more accurate. It has the advantages of being fast, sensitive, highly specific, easy to operate, and low in cost. BRIEF DESCRIPTION OF THE DRAWINGS
[0076] Figure 1 The figure is the gel electrophoresis diagram of nucleic acid extraction from different strains using different alkaline reagents; M is Marker; NC is negative control; the order of samples is: 1, Staphylococcus aureus; 2, Pseudomonas aeruginosa; 3, Acinetobacter baumannii; 4, Klebsiella pneumoniae; 5, Rhizopus oryzae; 6, Mucor circinelloides.
[0077] Figure 2 The effect of adding specific probes on the detection results.
[0078] Figure 3A-3D The initial screening results were obtained by optimizing the primer pairs for Mucor amplification; among them: Figure 3A for Figure 3B-Figure 3D Summary diagram of Figure 3B The sample concentration of Mucor was 1 ng / μl; Figure 3C The sample concentration of Mucor was 0.1 ng / μl; Figure 3D The sample concentration of Mucor is 0.01 ng / μl; the primer-probe pair combination red is: primer-probe combination 1; pink is: primer-probe combination 2; green is: primer-probe combination 3; blue is: primer-probe combination 4.
[0079] Figure 4 The test strip screening results; the sequence of primer-probe combination is:
[0080] 1: Muc-F1 / Muc-R1 / Muc-PR2;
[0081] 2: Muc-F1 / Muc-R2 / Muc-PR2;
[0082] 3: Muc-F2 / Muc-R1 / Muc-PR2;
[0083] 4:Muc-F2 / Muc-R2 / Muc-PR2.
[0084] Figure 5The figure is the gel electrophoresis diagram of the detection results of different markers; lanes 1-8 are: 1. RPA product labeled with digoxigenin; 2. RPA product labeled with digoxigenin combined with digoxigenin antibody-5; 3. RPA product labeled with digoxigenin combined with digoxigenin antibody-6; 4. RPA product labeled with digoxigenin combined with digoxigenin antibody-12; 5. RPA product labeled with digoxigenin combined with digoxigenin antibody-13; 6. RPA product labeled with digoxigenin combined with digoxigenin antibody-14; 7. RPA product labeled with FITC; 8. RPA product labeled with FITC combined with FITC antibody.
[0085] Figure 6 For the selection of biotin and digoxigenin labeling concentrations; lanes 1-8 are: 1. RPA product labeled with biotin and digoxigenin (labeled product); 2. Labeled product: SA=4:1; 3. Labeled product: SA=2:1; 4. Labeled product: SA=1:1; 5. Labeled product: SA=1:2; 6. Labeled product: DIG-13=4:1; 7. Labeled product: DIG-13=2:1; 8. Labeled product: DIG-13=1:1.
[0086] Figure 7 Optimization of the sample release buffer.
[0087] Figure 8 Specific detection of test strips for different strain samples.
[0088] Fig. 9 The results of the primer pair sensitivity test strip test; the sample order is 1:2.5*10 7 CFU / ml, 2:2.5*10 6 CFU / ml, 3:2.5*10 5 CFU / ml, 4:2.5*10 4 CFU / ml, 5:2.5*10 3 CFU / ml, 6:2.5*10 2 CFU / ml, 7: sterile water.
[0089] Fig.10 Schematic diagram of the identification system for microbial species.
[0090] Fig.11 A schematic diagram of the structure of an electronic device. DETAILED DESCRIPTION
[0091] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0092] In order to further explain the technical means and effects adopted by the present invention, the technical solution of the present invention is further described below in conjunction with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
[0093] Rhizopus arrhizus and Mucor circinellodies both belong to the genus Mucor. Mucor in the embodiments of the present invention is the abbreviation of Mucor circinellodies.
[0094] Example 1 Optimization of sample nucleic acid extraction method
[0095] First, the present invention provides a method for rapidly extracting a genome DNA sample of Mucor. The steps of extracting a Mucor sample with a sample release agent are as follows: taking 20 μl of the sample, adding 95 μl of 0.1M KOH, 0.5mM EDTA, and vortexing to mix; placing in a 90°C metal bath for incubation for 5 minutes; then standing at room temperature to restore the temperature to room temperature, a flocculent precipitate is precipitated, placing in a centrifuge at 10,000 rpm for 2 minutes, taking the supernatant and adding a sample preservation solution (Tris-HCl buffer, pH 8.0, 20 μl) to obtain an extracted genome solution.
[0096] The sample crude extraction method was tested for fungi, Gram-positive bacteria, and Gram-negative strains. For the selection of alkaline reagents, 0.1M sodium hydroxide (NaOH) and 0.1M potassium hydroxide (KOH) were selected as the test reagents, and the remaining steps were consistent with the sample release agent treatment method for Mucor. The extracted Mucor sample DNA was verified by PCR amplification. The Mucor-specific amplification primers and probe sequences are shown in Table 3; for the primer pair verified by bacteria, 16sDNA-F / R (see Table 3) was selected, and for the primer pair verified by fungi, ITS1 / ITS4 primer pair (see Table 3) was selected. The PCR amplification system and amplification procedure are shown in Tables 1 and 2:
[0097] Table 1 PCR amplification system
[0098]
[0099] Table 2 PCR amplification program
[0100]
[0101] The amplification results were identified using 2% agarose gel. Figure 1 As shown. Figure 1 It can be seen that the selection of potassium hydroxide (KOH) as the alkaline hydrolysis agent in the lysis reagent can play a significant role in the extraction.
[0102] Example 2 Addition of probes to the system
[0103] For the traditional RPA amplification combined with test strip detection method, only a pair of labeled forward and reverse primers need to be designed, but primer dimers will be generated, resulting in false positive test results. This method adds a labeled specific probe (SEQ ID NO: 6) to the RPA amplification, which can make the primer dimers undetectable in the test strip.
[0104] Specific results such as Figure 2 As shown: When the probe is added, the T line of NC in the amplification system does not appear, and if the probe is not added, the primer dimers that appear will bind to the T line and cause a false positive.
[0105] Example 3 Optimization and screening of primer pairs for RPA amplification of Mucor
[0106] The present invention provides a primer pair sequence for specific amplification of Mucor including: SEQ ID NO: 1-4, wherein the fragment size of the product obtained by RPA amplification of the primer pair sequence is about 205 bp. SEQ ID NO: 5-6 are probe sequences, and the sequence information is shown in Table 3:
[0107] Table 3 Amplification primer pairs and probe sequences
[0108]
[0109] Note: 1. "F", "R" and "PR" in the primer names represent the upstream, downstream and probe sequences of the primers respectively.
[0110] 2. FAM-dT is a FAM labeling group, DIG-dT is a DIG labeling group, BHQ1-dT is a BHQ1 labeling group, THF is a tetrahydrofuran molecule, and C3-spacer is a blocking group at the 3' end. The 5' end of the reverse primer (Muc-R1, Muc-R2) is labeled with Biotin.
[0111] 3. The two probes Muc-PR1 and Muc-PR2 have the same sequence but different labels. Muc-PR1 is labeled with FAM fluorescent signal and BHQ1 quenching group for fluorescence screening; Muc-PR2 is labeled with DIG antibody for screening and detection on test strips.
[0112] 3.1 Fluorescence screening
[0113] (1) According to the arranged sample sequence, the corresponding samples are marked on the PCR reaction 96-well plate (i.e., reaction plate, whose naming rule is "experiment date-sample label-site information") or 200 μl reaction tube of the biotechnology. The Mucormycosis (CBS 394.68) bacterial liquid samples are transferred from the sample tube in sequence with a pipette. The nucleic acid samples of the Mucormycosis liquid are extracted according to the optimized nucleic acid extraction method of Example 1. The nucleic acid sample should be added to the bottom of the reaction well; if the sample is not added to the bottom of the reaction well during the sample addition process, it should be centrifuged briefly after the sample addition is completed, and the extracted Mucor genomic DNA product is obtained after the reaction is completed. The samples used in the screening process are: 1 ng / μl, 0.1 ng / μl, 0.01 ng / μl of the extracted Mucor samples, and sterile water (NC). These four samples are screened and tested.
[0114] (2) Amplification was performed using the primer probe pairs in Table 3, primer probe pair combination 1: Muc-F1 / Muc-R1 / Muc-PR1, primer probe pair combination 2: Muc-F1 / Muc-R2 / Muc-PR1, primer probe pair combination 3: Muc-F2 / Muc-R1 / Muc-PR1, and primer probe pair combination 4: Muc-F2 / Muc-R2 / Muc-PR1.
[0115] (3) Configure the RPA reaction system according to Table 4:
[0116] Table 4 RPA reaction system
[0117]
[0118] After the system is configured as above, vortex mix, add 2.5 μl of the activator in the DNA constant temperature rapid amplification kit, vortex mix, and place in the ABI7300 real-time fluorescence quantitative PCR reaction instrument for constant temperature reaction at 39°C for 20 minutes.
[0119] (4) Fluorescence curve results are as follows Figure 3A-3D As shown:
[0120] Different primer probe pair combinations were screened, where the red primer probe pair combination is primer probe combination 1; the pink primer probe pair combination is primer probe combination 2; the green primer probe pair combination is primer probe combination 3; and the blue primer probe pair combination is primer probe combination 4. Primer probe pair combination 1: Muc-F1 / Muc-R1 / Muc-PR1, primer probe pair combination 2: Muc-F1 / Muc-R2 / Muc-PR1, primer probe pair combination 3: Muc-F2 / Muc-R1 / Muc-PR1, primer probe pair combination 4: Muc-F2 / Muc-R2 / Muc-PR1, these four pairs of primer probes have shorter signal values and reaction threshold time. Therefore, these four pairs of primer probes were selected for further testing.
[0121] 3.2 Test strip screening
[0122] (1) According to the arranged sample sequence, the corresponding samples are marked on the PCR reaction 96-well plate (i.e., reaction plate, whose naming rule is "experiment date-sample label-site information") or 200μl reaction tube of the biotechnology. Use a pipette to transfer the Mucormycosis (CBS 394.68) bacterial liquid samples from the sample tube in sequence. Extract the Mucormycosis liquid samples according to the above optimized extraction method. The sample should be added to the bottom of the reaction well; if the sample is not added to the bottom of the reaction well during the addition process, it should be centrifuged briefly after the addition is completed. After the reaction is completed, the extracted Mucor genomic DNA product is obtained. The samples used in the screening process are: 0.01ng / μl, 1pg / μl, 0.1pg / μl, and sterile water (NC) extracted from Mucor. These four samples are screened and tested.
[0123] (2) Amplification was performed using the primer-probe pairs listed in the table, Muc-F1 / Muc-R1 / Muc-PR2; Muc-F1 / Muc-R2 / Muc-PR2; Muc-F2 / Muc-R1 / Muc-PR2; and Muc-F2 / Muc-R2 / Muc-PR2.
[0124] (3) Prepare the RPA reaction system according to Table 5:
[0125] Table 5 RPA reaction system
[0126]
[0127] After configuring the system as above, vortex mix, add 2.5 μl of the activator in the DNA constant temperature rapid amplification kit, vortex mix, and incubate in a 39°C constant temperature bath for 10 minutes.
[0128] (4) For test strip detection: Take 15 μl of the amplified product and add it to 75 μl of sample buffer. Vortex to mix well and then add it to the treated test strip. Wait for about 3 minutes to determine whether it is positive or negative.
[0129] result Figure 4 As shown. Figure 4It can be seen that for the third pair of primer-probe combinations, samples with a detection sample concentration of 0.1pg / μl can also be detected, while the sensitivity of the remaining primer-probe combinations is not as good as that of the first pair of primer-probe combinations. Therefore, the primer-probe combination Muc-F1 / Muc-R1 / Muc-PR2 is more obvious for the identification result. For low-concentration samples, primer-probe combinations with poor amplification efficiency may not amplify the target band, while for primer-probe combinations with higher amplification efficiency, they can amplify the target band, thus proving that the primer-probe combination provided by the present invention can improve the sensitivity of detection.
[0130] Example 4 Preparation of digoxin antibody and FITC antibody
[0131] The following homemade antibodies are for cost considerations, and it is not necessary to use the homemade antibodies of the present invention. Those skilled in the art can prepare antibodies according to conventional methods, such as by the following subclone screening, hybridoma cells are inoculated into mice to collect ascites, and the method of purifying ascites is prepared and screened to obtain the target antibody with good specificity. Alternatively, conventional commercially available digoxin antibodies and FITC antibodies can also be selected. As long as the antibody used can produce a polymer binding with the RPA amplification product with the corresponding antigen marker, the technical effect of the present invention can be achieved.
[0132] The monoclonal antibody used in the example was developed on Balb / c mice using digoxin-BSA complex (Shanghai Maiye Biotechnology Co., Ltd., catalog number: Digoxin-BSA 230510#) as an immunogen. The first intradermal immunization was performed using digoxin-BSA complex (100 μg, as an immunogen) in 100ul emulsion prepared with Freund's complete adjuvant, and 100 μg of immunogen in 100μl emulsion prepared with Freund's incomplete adjuvant was used for enhanced immunization 25 days later. 50 μg of immunogen was used for intradermal immunization twice, with an interval of 4 weeks, and then 50 μg of immunogen was used in 100μl Hanks balanced salt solution (China Bishi Biotechnology Co., Ltd.) for intravenous and intraperitoneal prefusion promotion (the IgG1 antibody strain in the example was obtained by fusion at the first immunization). Hybridoma cell lines secreting digoxin-specific antibodies were produced using standard fusion technology. After extensive screening, several anti-digoxin antibody clones with good specificity were selected for the development of rapid detection and screening of Mucor.
[0133] Antibody subtype testing: A commercially available antibody subtype identification kit (ELISA) was used to identify the subtypes of several digoxin-specific antibodies that were screened. The identification results are shown in Table 6:
[0134] Table 6 Anti-digoxin antibody subtype identification results
[0135]
[0136] The monoclonal antibody used in the example was developed on Balb / c mice using FITC-OVA complex (Shanghai Maiye Biotechnology Co., Ltd., catalog number: FITC-OVA 240206#) as an immunogen. The first intradermal immunization was performed with FITC-OVA complex (100 μg, as an immunogen) in 100 μl emulsion prepared with Freund's complete adjuvant, and 25 days later, 100 μg of immunogen in 100 μl emulsion prepared with Freund's incomplete adjuvant was used for enhanced immunization. Then, 50 μg of immunogen was used for intradermal immunization twice, with an interval of 4 weeks, and then 50 μg of immunogen was used for intravenous and intraperitoneal prefusion promotion in 100 μl Hanks balanced salt solution (China Bishi Biotechnology Co., Ltd.) (the IgG1 antibody strain in the example was obtained by fusion at the first immunization). Hybridoma cell lines secreting digoxin-specific antibodies were produced using standard fusion technology. After extensive screening, anti-FITC antibody clones with good specificity were selected for the development of rapid detection of Mucor.
[0137] Antibody subtype testing: The commercially available antibody subtype identification kit (ELISA) was used to identify the subtype FITC-6 of the screened anti-FITC specific antibodies. The identification results are shown in Table 7:
[0138] Table 7 Identification results of anti-FITC antibody subtype FITC-6
[0139]
[0140] Example 5 Screening of markers and antibodies thereof
[0141] In this example, Pseudomonas aeruginosa was used as an example to test the markers and antibodies. The primers for Pseudomonas aeruginosa (PA-lasB-F3 / R3) are shown in Table 8. We selected two markers, digoxigenin (DIG) and fluorescein isothiocyanate (FITC), and marked them on the reverse primer (PA-lasB-R3) for performance comparison and identification. The amplification method is consistent with the PCR amplification system amplification detection method for detecting Mucor in Table 1 described in Example 1. The amplified PCR products labeled with digoxigenin were incubated with digoxigenin antibodies (digoxigenin antibody-5, digoxigenin antibody-6, digoxigenin antibody 12, digoxigenin antibody-13 or digoxigenin antibody-14) at room temperature for 3 minutes; the amplified PCR products labeled with FITC were incubated with FITC antibodies at room temperature for 3 minutes. (Wherein the digoxigenin antibody and FITC antibody are prepared by Example 4). Finally, the incubated reactants were subjected to agarose gel electrophoresis to identify the binding efficiency of the antibody and the labeled PCR product. The identification results are shown in the figure. Figure 5 shown.
[0142] Depend on Figure 5It can be seen that the PCR amplification products of lanes 4 and 5 can produce multimers with digoxigenin antibody, and the multimer band produced in lane 5 is brighter, indicating that digoxigenin antibody-13 can produce multimers with PCR amplification products and its efficiency is higher than that of other lanes. Therefore, digoxigenin was selected as the primer marker and digoxigenin antibody-13 as the subsequent labeling antibody.
[0143] Table 8 Pseudomonas aeruginosa PCR amplification primer pair sequence
[0144]
[0145] Example 6 Selection of biotin and digoxigenin labeling concentrations
[0146] In this example, Pseudomonas aeruginosa is used as an example to screen the concentrations of biotin and digoxigenin labels (the primers and probe sequences used for amplification are shown in Table 8, and the 5' end of the reverse primer PA-lasB-R3 is labeled with Biotin). For the markers biotin and digoxigenin on the PCR amplification product, they need to be combined with streptavidin (SA) and digoxigenin antibody on the test strip later, and now it is necessary to screen the concentration ratio of biotin and digoxigenin. The remaining steps are consistent with the Mucor amplification detection method described in Example 1. The PCR amplification products labeled with biotin and digoxigenin after PCR amplification are gradient screened with streptavidin (SA) and digoxigenin antibody (DIG-13) according to different molar concentration ratios, and incubated at room temperature for 3 minutes, and then agarose gel electrophoresis is performed to identify the binding efficiency. The electrophoresis results are shown in the figure. Figure 6 shown.
[0147] Depend on Figure 6 It can be seen that for lanes 4 and 5, the PCR amplification product can produce significant multimer binding with SA; for lane 8, the PCR amplification product can produce significant multimer binding with DIG-13, indicating that the subsequent polymer amplification of the signal value can be performed through the polymer. Therefore, the concentration of PCR amplification product: SA: DIG-13 = 1:1:1 was selected for the test strip detection.
[0148] Example 7 Sample Release Buffer Optimization
[0149] If the sample is directly tested on the test strip after RPA amplification, DIG-13 cannot be displayed on the test strip (because the amplified sample is viscous, which makes it impossible to perform capillary action and cannot be displayed on the test strip). Therefore, the sample release buffer is optimized. Select 2.5*10 5Nucleic acid extraction and RPA amplification were performed on Mucor samples with a sample concentration of CFU / ml (the primer probe combination used was SEQ ID NO: 1, 3 and 6), and water, PBS, and PBST+0.05% Triton solution were selected as sample release buffers for comparative detection tests. The results are shown in Figure 7 shown.
[0150] From the comparative test of different sample release buffers, it can be seen that PBST+0.05% Triton solution can fully release the amplified sample and obtain a more sensitive detection.
[0151] Example 8 Preparation of Test Strips
[0152] 1. Preparation of labeled microspheres
[0153] Take two tubes of 200 μl of 200 nm blue microspheres (Jiaxing Maijin Biotechnology Co., Ltd.), add 1400 μl of activation buffer (HEPES solution 5.6 g / L pH 7.45), and mix by pipetting; add 200 μl of microsphere 1 to the first tube 1mg / ml streptavidin (SA) solution, mouse anti-human antibody (0.2mg, Merck, catalog number: I6760) was added to the second tube of microspheres 2; 1mg / mL EDC (1-ethyl-(3-dimethylaminopropyl) carbodiimide) was added to the tube wall, and the mixture was quickly shaken up and down to mix, and the mixture was placed in a constant temperature reaction for 60mins (24℃, 100rpm); after the reaction, each tube was ultrasonicated for 5 times, 100μl of blocking agent (CE510 solution) was added, and then ultrasonicated for 5 times, and the mixture was placed in a constant temperature shaker for blocking for 90mins (100rpm, 24℃); after the blocking was completed, centrifuged for 20min (13000rpm, 4℃), the supernatant was discarded, and the precipitate was resuspended with 2ml PBS storage buffer; it was stored in a refrigerator at 2-8℃ for later use.
[0154] 2. Gold coating on test strips
[0155] The two tubes of labeled microsphere solutions prepared above were diluted 20 times with PBS solution, and then the microsphere 1 was sprayed with gold at a concentration of 6 μl / cm, and then dried in a dryer; then the microsphere 2 was sprayed with gold and dried. Digoxin antibody (DIG-13) was sprayed on the nitrocellulose membrane using a film spray gold instrument as the test line (T line) and goat anti-mouse antibody (Sigma, catalog number: A9309-1mL) as the quality control line (C line).
[0156] Take 15μl of the amplified product and add it to 75μl of sample buffer, vortex mix, and then add it to the treated test strip. Wait for about 3 minutes to judge whether it is positive or negative. When both the test line (T line) and the quality control line (C line) of the test strip have bands, it means that the result is positive and Mucor exists; if only the quality control line has a band and there is no band at the test line, it means that the result is negative and Mucor does not exist; if no band appears on the quality control line, the result is invalid.
[0157] Example 9 Sample-specific test strip detection
[0158] Specific detection was performed on samples of different strains. The remaining steps were consistent with the RPA detection method for detecting Mucor in Example 3. RPA amplification verification was performed on the extracted DNA of different samples (the primer probe combination used was SEQ ID NO: 1, 3 and 6). The results are shown in FIG. Figure 8 As shown, the samples are: Rhizopus arrhizus (ATCC 5604), Mucor circinellodies (CBS 394.68), Candida albicans, yeast, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and NC.
[0159] The above different strain types are common strains. Figure 8 It can be seen that the primer-probe combination of the present invention can specifically detect Mucor samples and is exclusive and specific to Mucor samples.
[0160] Example 10 Sample sensitivity test strip detection
[0161] For the Mucor strain samples, gradient dilution was performed with sterile saline, using different concentrations (1:2.5*10 7 CFU / ml, 2:2.5*10 6 CFU / ml, 3:2.5*10 5 CFU / ml, 4:2.5*10 4 CFU / ml, 5:2.5*10 3 CFU / ml, 6:2.5*10 2 CFU / ml) samples were tested for sensitivity. The remaining steps were consistent with the RPA detection method for Mucor in Example 3. The extracted Mucor sample DNA was amplified by RPA (the primer probe combination used was SEQ ID NO: 1, 3 and 6). The results are shown in Fig. 9 , where the sample order is 1:2.5*10 7 CFU / ml, 2:2.5*10 6 CFU / ml, 3:2.5*10 5CFU / ml, 4:2.5*10 4 CFU / ml, 5:2.5*10 3 CFU / ml, 6:2.5*10 2 CFU / ml, 7: sterile water.
[0162] Depend on Fig. 9 It can be seen that the primer pair provided by the present invention has a sample concentration of 2.5*10 3 CFU / ml, it can still be significantly detected. This proves that the primer-probe combination of the present invention has a high sensitivity. And from the trend of the band depth, it can be seen that the lower the sample concentration, the lighter the positive band, so the concentration of the strain in the sample can be seen from the depth of the positive band.
[0163] Example 11 Microbial Species Identification System
[0164] System 61 for identification of microbial species: information collection module 51, identification module 52 and data storage module 53 (see Fig.10 ).
[0165] The information collection module 51 is used to collect the test strip results and identify the uploaded result pictures;
[0166] The identification module 52 is used to determine whether the sample to be identified is Mucor, and automatically upload and save the data. The judgment criteria for the identification are:
[0167] a. If there is no quality control line C, the identification result is considered invalid; if there is a quality control line C, proceed to step b;
[0168] b. If there is a T line, the result is determined to be positive for Mucor; if there is no T line, the result is determined to be negative for Mucor;
[0169] The data storage module 53 is used to store information, including user information, detection time and / or judgment results, to facilitate the subsequent recording and tracking of pathogen infection information.
[0170] Embodiment 12 Electronic device
[0171] This embodiment provides an electronic device, which can be expressed in the form of a computing device (for example, a server device), including a memory, a processor, and a computer program stored in the memory and executable on the processor, wherein the microbial species identification system of Embodiment 11 of the present invention can be implemented when the processor executes the computer program.
[0172] Fig.11 The hardware structure diagram of this embodiment is shown, and the electronic device 9 specifically includes:
[0173] At least one processor 91, at least one memory 92, and a bus 93 for connecting different system components (including the processor 91 and the memory 92), wherein:
[0174] The bus 93 includes a data bus, an address bus, and a control bus.
[0175] The memory 92 includes a volatile memory, such as a random access memory (RAM) 921 and / or a cache memory 922 , and may further include a read-only memory (ROM) 923 .
[0176] The memory 92 also includes a program tool 925 having a set (at least one) of program modules 924, such program modules 924 including but not limited to: an operating system, one or more application programs, other program modules and program data, each of which or some combination may include the implementation of a network environment.
[0177] The processor 91 executes various functional applications and data processing by running the computer programs stored in the memory 92, such as processing the sequence information in the sample and the sequence information in the database.
[0178] The electronic device 9 can further communicate with one or more external devices 94 (e.g., keyboards, pointing devices, etc.). Such communication can be performed through an input / output (I / O) interface 95. In addition, the electronic device 9 can also communicate with one or more networks (e.g., local area networks (LANs), wide area networks (WANs), and / or public networks, such as the Internet) through a network adapter 96. The network adapter 96 communicates with other modules of the electronic device 9 through a bus 93. It should be understood that, although not shown in the figure, other hardware and / or software modules can be used in conjunction with the electronic device 9, including but not limited to: microcode, device drivers, redundant processors, external disk drive arrays, RAID (disk array) systems, tape drives, and data backup storage systems, etc.
[0179] It should be noted that although several units / modules or sub-units / modules of the electronic device are mentioned in the above detailed description, this division is merely exemplary and not mandatory. In fact, according to the embodiments of the present application, the features and functions of two or more units / modules described above can be embodied in one unit / module. Conversely, the features and functions of one unit / module described above can be further divided into multiple units / modules to be embodied.
[0180] Embodiment 13 Computer readable storage medium
[0181] An embodiment of the present invention provides a computer-readable storage medium having a computer program stored thereon, and when the program is executed by a processor, the steps of the microbial species identification system of embodiment 11 of the present invention are implemented.
[0182] The readable storage medium may include but is not limited to: a portable disk, a hard disk, a random access memory, a read-only memory, an erasable programmable read-only memory, an optical storage device, a magnetic storage device or any suitable combination of the above.
[0183] In a possible implementation manner, the present invention may also be implemented in the form of a program product, which includes program codes. When the program product is run on a terminal device, the program codes are used to enable the terminal device to execute the steps of implementing the above-mentioned identification method.
[0184] The program code for executing the present invention may be written in any combination of one or more programming languages, and may be executed entirely on a user device, partially on a user device, as an independent software package, partially on a user device and partially on a remote device, or entirely on a remote device.
Claims
1. A primer pair for specific amplification of Mucor, the primer pair comprising a forward primer and a reverse primer, characterized in that: The nucleotide sequence of the forward primer is shown in SEQ ID NO: 1 or 2, and the nucleotide sequence of the reverse primer is shown in SEQ ID NO: 3 or 4; Preferably, the 5' end of the reverse primer is conjugated with a label, and the label is preferably biotin.
2. A gene probe coupled with digoxigenin labeling, characterized in that: The nucleotide sequence of the gene probe is shown in SEQ ID NO:
6.
3. A primer-probe combination, characterized in that: The primer-probe combination comprises the primer pair according to claim 1 and / or the gene probe according to claim 2; Preferably, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:1 and whose nucleotide sequence of the reverse primer is shown in SEQ ID NO:3, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:6; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:1 and whose nucleotide sequence of the reverse primer is shown in SEQ ID NO:4, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:6; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:2 and whose nucleotide sequence of the reverse primer is shown in SEQ ID NO:3, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:6; or, the primer-probe combination comprises a primer pair whose nucleotide sequence of the forward primer is shown in SEQ ID NO:2 and whose nucleotide sequence of the reverse primer is shown in SEQ ID NO:4, and a gene probe whose nucleotide sequence is shown in SEQ ID NO:6; More preferably, the 5' end of the reverse primer is conjugated with a label, and the label is preferably biotin.
4. A test strip comprising a sample pad, a conjugate pad, a nitrocellulose membrane and an absorption pad, characterized in that: The conjugate pad comprises microsphere solution 1 and microsphere solution 2; the nitrocellulose membrane comprises a detection line T line and a quality control line C line; The microsphere solution 1 contains microspheres labeled with streptavidin; the microsphere solution 2 contains microspheres labeled with mouse anti-human antibody; the detection line T contains digoxigenin antibody, and the quality control line C contains goat anti-mouse antibody; Preferably, the test strip meets one or more of the following conditions: (1) The particle size of the microspheres is 100-300 nm, for example, 200 nm; (2) the molar concentration ratio of streptavidin in the microsphere solution 1 to the digoxigenin antibody in the detection line T is 1:1; and, (3) The binding pad is a colloidal gold binding pad, and the amount of gold sprayed onto the microspheres is, for example, 6 μl / cm.
5. Use of the primer pair according to claim 1, the gene probe according to claim 2, the primer-probe combination according to claim 3 and / or the test strip according to claim 4 in preparing a kit for identifying Mucor.
6. A kit for identifying Mucor, characterized in that: The kit comprises one or more selected from the group consisting of the primer pair as claimed in claim 1, the gene probe as claimed in claim 2, the primer-probe combination as claimed in claim 3, and the test strip as claimed in claim 4; Preferably, the kit further comprises a nucleic acid extraction reagent and / or a sample release buffer; the nucleic acid extraction reagent is an alkaline reagent, and the sample release buffer comprises a phosphate buffered saline solution; More preferably, the nucleic acid extraction reagent is KOH and / or the sample release buffer is PBST+0.05% Triton.
7. A method for identifying Mucor in a sample for non-diagnostic purposes, characterized in that: The method comprises using the primer pair as claimed in claim 1, the gene probe as claimed in claim 2, the primer-probe combination as claimed in claim 3, the test strip as claimed in claim 4 and / or the kit as claimed in claim 6; Preferably, the method comprises the following steps: (I) performing RPA amplification on the DNA extracted from the sample to be tested using the primer pair according to claim 1, the gene probe according to claim 2, and / or the primer-probe combination according to claim 3 to obtain an RPA amplification product; and, (II) mixing the RPA amplification product and the sample release buffer in a volume ratio of 1:5, and adding the mixture to the test strip as claimed in claim 4; More preferably, the method further comprises: (III) determining whether Mucor is present in the sample to be tested based on the information on the test strip obtained after implementing step (II); The judgment conditions are: when the test strip has a detection line T line and a quality control line C line, it means that the result is positive and Mucor exists in the sample to be tested; when the test strip has only a quality control line C line but no detection line T line, it means that the result is negative and Mucor does not exist in the sample to be tested; when the test strip has no quality control line C line, the result is invalid.
8. A Mucor identification system, characterized in that: The identification system comprises: (1) an information collection module: used to collect information on the test strip obtained by using the method according to claim 7; and, (2) Identification module: used to determine whether the sample to be tested contains Mucor; the judgment criteria are: a. If there is no quality control line C, the identification result is considered invalid; if there is a quality control line C, proceed to step b; b. If there is a T line, it is judged as Mucor positive; if there is no T line, it is judged as Mucor negative; (3) Data storage module: used to store user information, detection time, judgment results and other information.
9. A computer-readable storage medium having a computer program stored thereon, characterized in that: The computer program implements the authentication system according to claim 8.
10. An electronic device comprising a memory, a processor and a computer program stored in the memory and executable on the processor, characterized in that: When the processor executes the computer program, the authentication system according to claim 8 is implemented.
11. Use of the primer pair according to claim 1, the gene probe according to claim 2, the primer-probe combination according to claim 3, the test strip according to claim 4, the kit according to claim 6, the identification system according to claim 8, the computer-readable storage medium according to claim 9 and / or the electronic device according to claim 10 in identifying whether a sample contains Mucor; Preferably, the use is for non-diagnostic purposes.
